search
Back to results

Embolization for the Treatment of Pain Secondary to Adhesive Capsulitis (AES)

Primary Purpose

Frozen Shoulder, Adhesive Capsulitis

Status
Unknown status
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Arterial Embolization of the Shoulder
Sponsored by
Vascular Institute of Virginia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Frozen Shoulder

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • moderate to severe shoulder pain (VAS greater than 40mm), and
  • diagnosis of adhesive capsulitis, and
  • age > 21, and
  • pain refractory to at least 30 days of conservative therapy (pain medications, physical therapy, etc.)

Exclusion Criteria:

  • current local infection, or
  • life expectancy less than 6 months, or
  • known advanced atherosclerosis, or
  • rheumatoid or infectious arthritis, or
  • prior shoulder replacement surgery, or
  • uncorrectable coagulopathy as defined by INR > 2.5 or platelets < 30,000, or
  • iodine allergy resulting in anaphylaxis, or
  • renal dysfunction as defined by GRF of < 45, or
  • contraindication for magnetic resonance imaging, or
  • known complete full thickness tear of rotator cuff, or
  • currently pregnant

Sites / Locations

  • Vascular Institute of VirginiaRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Arterial Embolization of the Shoulder (AES)

Arm Description

Patients in this study will receive the arterial embolization of the shoulder (AES) procedure. The primary aims will be to determine if arterial embolization of the shoulder (AES) will reduce pain and improve range of motion (ROM) caused by adhesive capsulitis.

Outcomes

Primary Outcome Measures

Patient Pain
The pain intensity is assessed using a visual analogue scale (VAS), which is a horizontal line 100 mm in length. Subjects mark the VAS with a single vertical line to indicate their current pain level, with 0 mm representing "No Pain" and 100 mm representing "Worst Possible Pain". Pain will be assessed at each of the patient's follow-up visits and used to measure the change from baseline (prior to the AES procedure). The investigators will use this to measure if the patient's pain level decreases.
Patient Function
The American Shoulder and Elbow Surgeons Shoulder Score (ASES) will be used to measure function. This is a score derived from a questionnaire in which the patient answers questions regarding range of motion, stiffness, and pain and how it affects the ability to function.

Secondary Outcome Measures

Reduction in Medication
Reduction in the number or strength of previously initiated medical therapy (e.g. NSAIDs).
Improvement of Range of Motion
Patients' range of motion will be assessed prior to undergoing embolization and at 1,3, and 6 month follow ups.

Full Information

First Posted
September 17, 2018
Last Updated
September 19, 2018
Sponsor
Vascular Institute of Virginia
Collaborators
Terumo Medical Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT03676829
Brief Title
Embolization for the Treatment of Pain Secondary to Adhesive Capsulitis
Acronym
AES
Official Title
Embolization for the Treatment of Pain Secondary to Adhesive Capsulitis
Study Type
Interventional

2. Study Status

Record Verification Date
September 2018
Overall Recruitment Status
Unknown status
Study Start Date
September 13, 2018 (Actual)
Primary Completion Date
August 2019 (Anticipated)
Study Completion Date
December 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vascular Institute of Virginia
Collaborators
Terumo Medical Corporation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is to test a new treatment method, arterial embolization of the shoulder (AES), to reduce the severity of pain and improve range of motion (ROM), and to see if it can be performed safely.
Detailed Description
Purpose: The primary aims of this study are to determine if arterial embolization of the shoulder will reduce the severity of pain as well improve Range of Motion (ROM) caused by adhesive capsulitis and if it can be performed safely. The secondary aim is to determine if AES can result in the decreased necessity for ongoing conservative therapies, such as medication therapy and joint injections. Participants: Twenty patients with adhesive capsulitis, resulting in shoulder pain that is refractory to conservative therapies, who are not planning to undergo surgery within 6 months. Procedures (methods): This will be an open label 24-month pilot study with a small population undergoing AES to determine safety and efficacy. Clinical procedures and evaluations will consist of a preoperative screening assessment to determine if the potential study subject meets the inclusion and exclusion criteria, enrollment, surgical procedure for arterial embolization of the shoulder, and follow-up visits at 24 hours, 1, 3 & 6 months. An MRI will be performed at the 1-month visit to detect a change in capsular vascularity and to exclude complication.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Frozen Shoulder, Adhesive Capsulitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arterial Embolization of the Shoulder (AES)
Arm Type
Experimental
Arm Description
Patients in this study will receive the arterial embolization of the shoulder (AES) procedure. The primary aims will be to determine if arterial embolization of the shoulder (AES) will reduce pain and improve range of motion (ROM) caused by adhesive capsulitis.
Intervention Type
Device
Intervention Name(s)
Arterial Embolization of the Shoulder
Intervention Description
Arterial Embolization of the Shoulder (AES) is a new procedure that is being used to reduce pain and improve range of motion (ROM) caused by adhesive capsulitis. Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the shoulder, resulting in improvement of pain, stiffness and from adhesive capsulitis.
Primary Outcome Measure Information:
Title
Patient Pain
Description
The pain intensity is assessed using a visual analogue scale (VAS), which is a horizontal line 100 mm in length. Subjects mark the VAS with a single vertical line to indicate their current pain level, with 0 mm representing "No Pain" and 100 mm representing "Worst Possible Pain". Pain will be assessed at each of the patient's follow-up visits and used to measure the change from baseline (prior to the AES procedure). The investigators will use this to measure if the patient's pain level decreases.
Time Frame
6 months
Title
Patient Function
Description
The American Shoulder and Elbow Surgeons Shoulder Score (ASES) will be used to measure function. This is a score derived from a questionnaire in which the patient answers questions regarding range of motion, stiffness, and pain and how it affects the ability to function.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Reduction in Medication
Description
Reduction in the number or strength of previously initiated medical therapy (e.g. NSAIDs).
Time Frame
6 months
Title
Improvement of Range of Motion
Description
Patients' range of motion will be assessed prior to undergoing embolization and at 1,3, and 6 month follow ups.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: moderate to severe shoulder pain (VAS greater than 40mm), and diagnosis of adhesive capsulitis, and age > 21, and pain refractory to at least 30 days of conservative therapy (pain medications, physical therapy, etc.) Exclusion Criteria: current local infection, or life expectancy less than 6 months, or known advanced atherosclerosis, or rheumatoid or infectious arthritis, or prior shoulder replacement surgery, or uncorrectable coagulopathy as defined by INR > 2.5 or platelets < 30,000, or iodine allergy resulting in anaphylaxis, or renal dysfunction as defined by GRF of < 45, or contraindication for magnetic resonance imaging, or known complete full thickness tear of rotator cuff, or currently pregnant
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Julie Orlando, CCRC
Phone
703-763-5224
Email
jorlando@teamviv.com
First Name & Middle Initial & Last Name or Official Title & Degree
Molly Godin, RN
Phone
703-763-5224
Email
mgodin@teamviv.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sandeep Bagla, MD
Organizational Affiliation
Vascular Institute of Virginia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Vascular Institute of Virginia
City
Woodbridge
State/Province
Virginia
ZIP/Postal Code
22193
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Julie Orlando, CCRC
Phone
703-763-5224
Email
jorlando@teamviv.com
First Name & Middle Initial & Last Name & Degree
Molly Godin, RN
Phone
703-763-5224
Email
mgodin@teamviv.com
First Name & Middle Initial & Last Name & Degree
Sandeep Bagla, MD
First Name & Middle Initial & Last Name & Degree
Rachel Piechowiak, DO

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Embolization for the Treatment of Pain Secondary to Adhesive Capsulitis

We'll reach out to this number within 24 hrs